基础医学与临床 ›› 2009, Vol. 29 ›› Issue (8): 816-820.

• 研究论文 • 上一篇    下一篇

罗格列酮对大鼠急性心肌梗死再灌注后无复流的影响

何泉 雷寒 柳青 覃数 马康华 王曦   

  1. 重庆医科大学附属第一医院心内科 重庆医科大学附属第一医院心内科 重庆医科大学附属第一医院心血管外科 重庆
  • 收稿日期:2009-02-24 修回日期:2009-04-13 出版日期:2009-08-20 发布日期:2009-08-20
  • 通讯作者: 雷寒

Effect of rosiglitazone on no-reflow after reperfusion in rats with AMI

Quan HE, Han LEI, Qing LIU, Shu QIN, Kang-hua MA, Xi WANG   

  1. Department of Cardiology, the First Affiliated Hospital , Chongqing Medical University Department of Cardiology, the First Affiliated Hospital , Chongqing Medical University
  • Received:2009-02-24 Revised:2009-04-13 Online:2009-08-20 Published:2009-08-20
  • Contact: Han LEI,

摘要: 目的 探讨罗格列酮对急性心肌梗死(AMI)再灌注后无复流及内皮型一氧化氮合酶(eNOS)表达的影响。方法 结扎大鼠左冠状动脉前降支3 h后松解2 h建立AMI再灌注后无复流动物模型,将60只大鼠随机分为对照组、假手术组、罗格列酮组、罗格列酮+L-NNA(NOS抑制剂)组、L-NNA组;以伊文思蓝-硫磺素染色法检测大鼠心肌组织无复流范围;Western blot检测丝氨酸1177磷酸化内皮型一氧化氮合酶(p-eNOS Ser1177)蛋白表达,RT-PCR检测eNOS mRNA的表达。结果 (1)与对照组相比,罗格列酮组大鼠心肌组织无复流范围明显减小(P<0.05),而L-NNA+罗格列酮组无复流范围无显著差异;(2)罗格列酮组eNOS mRNA表达较对照组无显著差别,而p-eNOS Ser1177蛋白表达显著增强(P<0.05);结论 罗格列酮显著减小AMI再灌注后无复流范围,其机制与其促进再灌注后eNOS磷酸化,增加NO释放有关。

关键词: 罗格列酮, 急性心肌梗死, 无再流现象, 内皮型一氧化氮合酶

Abstract: Objective To investigate the effect of rosiglitazone on no-reflow and eNOS expression after reperfusion in rats with AMI. Methods Left anterior descending coronary artery was undergone 3 h of occlusion and 2 h of reperfusion to establish the model of no-reflow. 60 SD rats were randomly divided into the control group、the sham operated group、the rosiglitazone group、rosiglitazone plus L-NNA group、L-NNA group; thioflavin-S and Evan's blue were used to delineate the ligation area (LA) and area of no-reflow (ANR); Western blot for phosphorylated eNOS at Ser1177、RT-PCR for mRNA expression of eNOS were performed. Results (1)Compared with control group, area of no-reflow in rosiglitazone group were significantly reduced(P<0.05), but not in rosiglitazone plus L-NNA group; (2)Compared with the control group,there was no significant differences in mRNA expression of eNOS in rosiglitazone group, whereas Level of p-eNOS Ser1177 protein was significantly increased (P<0.05). Conclusions Rosiglitazone significantly reduced area of no-reflow after reperfusion in rats with AMI, the mechanism of which may be partly due to its role in improving phosphorylation of eNOS, and further increased production of NO.

Key words: Rosiglitazone, Acute myocardial infarction, No-reflow phenomenon, Endothelial nitric oxide synthase

中图分类号: